Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Neuroendocrine neoplasms
Prognosis
Real-world study
Somatostatin analogs
Somatostatin receptor
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
24 Sep 2024
24 Sep 2024
Historique:
received:
24
07
2024
accepted:
10
09
2024
medline:
24
9
2024
pubmed:
24
9
2024
entrez:
24
9
2024
Statut:
aheadofprint
Résumé
The somatostatin analogs (SSA) octreotide and lanreotide are a mainstay in the treatment of neuroendocrine tumors (NET). The two pivotal trials differed considerably in terms of patient characteristics and are not directly comparable. Further comparative data are lacking. This retrospective chart review study included patients with gastroenteropancreatic NET grade 1 or 2 who were treated with octreotide LAR or lanreotide autogel. The main aim was to compare the two SSA based on progression-free survival (PFS) and overall survival (OS) from treatment start. In total, 129 patients were analyzed, 60% (n = 77) had a small intestinal NET and 31% (n = 40) a pancreatic NET. Histologically, 34% (n = 44) had NET G1, 55% (n = 71) a NET G2, and 11% (n = 14) a NET G1/G2 unclassified. Lanreotide was used in 90 patients (70%) and octreotide in 39 patients (30%). Overall, the median PFS was 32.2 months (95% CI 23.0-42.9 months). No PFS difference (p = 0.8) was observed between lanreotide (29.8 months, 95% CI 18.7-48.5 months) and octreotide (36.0 months, 95% CI 23.2-68.2 months). Median OS from treatment start was calculated at 93.5 months (95% CI 71.1-132.9 months). Again, the median OS following lanreotide (113.4 months, 95% CI 62.3-NA months) or after octreotide (90.3 months, 95% CI 71.1-NA months) did not differ significantly (p > 0.9). Our long-term experience with octreotide and lanreotide in NET did not reveal differences in antitumor effectiveness. This is consistent with previous reports and might suggest that both SSA can be used interchangeably if needed.
Identifiants
pubmed: 39316250
doi: 10.1007/s12094-024-03732-w
pii: 10.1007/s12094-024-03732-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991–1002.
doi: 10.1016/j.neo.2017.09.002
pubmed: 29091800
pmcid: 5678742
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.
doi: 10.1001/jamaoncol.2017.0589
pubmed: 28448665
pmcid: 5824320
Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54.
doi: 10.1007/s12022-022-09708-2
pubmed: 35294740
Elvebakken H, Perren A, Scoazec JY, et al. A consensus-developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations. Neuroendocrinology. 2021;111(9):883–94.
doi: 10.1159/000511905
pubmed: 33002892
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.
doi: 10.1016/j.annonc.2020.03.304
pubmed: 32272208
Stueven AK, Kayser A, Wetz C, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019;20(12):3049.
doi: 10.3390/ijms20123049
pubmed: 31234481
pmcid: 6627451
Günther T, Tulipano G, Dournaud P, et al. International union of basic and clinical pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev. 2018;70(4):763–835.
doi: 10.1124/pr.117.015388
pubmed: 30232095
pmcid: 6148080
Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139(3):742–53.
doi: 10.1053/j.gastro.2010.07.002
pubmed: 20637207
Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of somatostatin signalling in neuroendocrine tumours. Int J Mol Sci. 2022;23(3):1447.
doi: 10.3390/ijms23031447
pubmed: 35163374
pmcid: 8836266
Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–88.
doi: 10.1111/j.1365-2036.2009.04174.x
pubmed: 19845567
La Salvia A, Modica R, Rossi RE, et al. Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists. Cancer Treat Rev. 2023;117:102560.
doi: 10.1016/j.ctrv.2023.102560
pubmed: 37088017
Rinke A, Müller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63.
doi: 10.1200/JCO.2009.22.8510
pubmed: 19704057
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.
doi: 10.1056/NEJMoa1316158
pubmed: 25014687
Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival. Neuroendocrinology. 2017;104(1):26–32.
doi: 10.1159/000443612
pubmed: 26731483
Allaw MB, Switchenko JM, Khalil L, et al. Comparing somatostatin analogs in the treatment of advanced gastroenteropancreatic neuroendocrine tumors. Oncology. 2022;100(3):131–9.
doi: 10.1159/000519605
pubmed: 35078191
Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, et al. External validity of somatostatin analogs trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study. Neuroendocrinology. 2022;112(1):88–100.
doi: 10.1159/000514808
pubmed: 33508849
Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172–85.
doi: 10.1159/000443167
pubmed: 26731013
Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol. 2005;45(7):836–44.
doi: 10.1177/0091270005277936
pubmed: 15951474
Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4(43):1686.
doi: 10.21105/joss.01686
Sjoberg D, Baillie M, Fruechtenicht C, Haesendonckx S, T T. ggsurvfit: Flexible Time-to-Event Figures. R package version 1.1.0. https://CRAN.R-project.org/package=ggsurvfit . Published 2024. Accessed 10 May 2024
Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible summary tables with the gtsummary package. R J. 2021;13(1):570–80.
doi: 10.32614/RJ-2021-053
Iannone R, Cheng J, Schloerke B, Hughes E, Lauer A, Seo J. gt: Easily Create Presentation-Ready Display Tables. R package version 0.10.1. https://CRAN.R-project.org/package=gt . Published 2024. Accessed 10 May 2024
Therneau T. A Package for Survival Analysis in R. R package version 3.6–4. https://CRAN.R-project.org/package=survival . Published 2024. Accessed 10 May 2024
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–6.
doi: 10.1016/0197-2456(96)00075-X
pubmed: 8889347
Kos-Kudła B, Castaño JP, Denecke T, et al. European neuroendocrine tumour society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol. 2023;35(12):e13343.
doi: 10.1111/jne.13343
pubmed: 37877341
Rinke A, Ambrosini V, Dromain C, et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol. 2023;35(6):e13309.
doi: 10.1111/jne.13309
pubmed: 37345509
Caplin ME, Pavel M, Phan AT, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71(2):502–13.
doi: 10.1007/s12020-020-02475-2
pubmed: 33052555
Klink AJ, Feinberg B, Yu HT, et al. Patterns of Care among real-world patients with metastatic neuroendocrine tumors. Oncologist. 2019;24(10):1331–9.
doi: 10.1634/theoncologist.2018-0798
pubmed: 31015313
pmcid: 6795156
Clarke CN, Cockrum P, Beveridge TJR, et al. Treatment patterns of long-acting somatostatin analogs for neuroendocrine tumors. J Health Econ Outcomes Res. 2023;10(2):121–31.
doi: 10.36469/jheor.2023.89300
pubmed: 38093906
pmcid: 10718524
Papantoniou D, Grönberg M, Thiis-Evensen E, et al. Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. Endocr Relat Cancer. 2023. https://doi.org/10.1530/ERC-22-0316 .
doi: 10.1530/ERC-22-0316
pubmed: 36629395
pmcid: 9986391
Pavel M, Ćwikła JB, Lombard-Bohas C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer. 2021;157:403–14.
doi: 10.1016/j.ejca.2021.06.056
pubmed: 34597974
Krishnan T, Safro M, Furlanetto DM, et al. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors. J Neuroendocrinol. 2024;36(1):e13360.
doi: 10.1111/jne.13360
pubmed: 38088132